Dan­ish biotech nabs No­vo Hold­ings sup­port in seed round for com­ple­ment plat­form

No­vo Hold­ings is pitch­ing in to Com­mit Bi­o­log­ics’ seed fund­ing for its re­search on “su­per­charg­ing” an­ti­bod­ies to turn on the com­ple­ment sys­tem, an ap­proach that could po­ten­tial­ly lead to treat­ments for blood can­cer and au­toim­mune dis­eases.

The €16 mil­lion ($17 mil­lion) raise, led by No­vo Hold­ings and Bio­qube Ven­tures, will help ac­cel­er­ate de­vel­op­ment of Com­mit’s so-called Bis­pe­cif­ic Com­ple­ment En­gag­ing (BiCE) plat­form. The funds should of­fer a run­way through the start of 2026, Com­mit Bi­o­log­ics CEO Kr­ish­na Polu told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER